| Bioactivity | (R)-Levrazoxane is enzymatically hydrolysed to one-ring open intermediates by dihydropyrimidine amidohydrolase (DPHase), which is present in the liver and kidney. The radiosensitizing efficiency of (R)-Levrazoxane towards EMT6 mouse mammary tumour cells is greater than that of Dexrazoxane (HY-B0581). (R)-Levrazoxane is promising for research of liver and kidney related diseases[1]. |
| CAS | 24613-06-7 |
| Formula | C11H16N4O4 |
| Molar Mass | 268.27 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hasinoff BB, et al. Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica. 1994 Oct;24(10):977-87. |
(R)-Levrazoxane
CAS: 24613-06-7 F: C11H16N4O4 W: 268.27
(R)-Levrazoxane is enzymatically hydrolysed to one-ring open intermediates by dihydropyrimidine amidohydrolase (DPHase),
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.